# US 2008/0187541 A1 · Helicobacter pylori adhesin binding group antigen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187541 A1
- Document ID: US20080187541A1
- Status: Published application
- Kind: A1
- Application number: 11/762,720
- Filed: 2007-06-13
- Published: 2008-08-07
- Earliest claimed: 1996-06-10
- Inventors: Thomas Boren; Anna Arnqvist; Lennart Hammarstrom; Staffan Normark; Dag Ilver
- Web page: https://patentgrep.com/patent/US20080187541A1

## CPC

- C07K 14/205: from Campylobacter (G)
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 31/04: Antibacterial agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/51: {comprising whole cells, viruses or DNA/RNA}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A novel Helicobacter pylori blood group antigen binding (BAB) adhesin protein was isolated and purified, whereby said protein or fractions thereof bind specifically to fucosylated blood group antigens. The protein sequence of said adhesin is disclosed in this application. Simultaneously the DNA sequences for two genes, babA and babB, producing highly similar proteins, are disclosed. Said adhesin and/or DNA is useful for diagnose and therapy and/or prophylaxis directed against H. pylori induced infections, e.g. gastritis and acid peptic disease, i.e. active vaccination. A new immunoglobulin composition, which exhibits specific activity to a Lewisb antigen binding Helicobacter pylori adhesin, or preferably, monoclonal and/or polyclonal antibodies to said adhesin offer a new and more efficient method of treatment and/or prevention of gastrointestinal diseases, caused by Helicobacter pylori or other Helicobacter species, i.e. passive vaccination.

## Claims

### Claim 1

A vaccine comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:6.

### Claim 2

A test kit comprising a monospecific antisera that recognizes a BabA antigen and comprises an immunoglobulin that binds said BabA antigen via a variable region, wherein said Bab A adhesin protein is produced using an isolated and purified bacterial blood group antigen binding protein (BabA) from Helicobacter pylori species, wherein said BabA protein binds specifically to fucosylated Lewisb type I and H-1 blood group antigen-glycoconjugates and,
wherein said BabA protein contains less than 20% bacterial protein impurities, has a molecular weight in the interval of 73 to 75 kDa as determined by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), and is not a HopA, HopB, HopC, HopD, or HopE protein.

### Claim 3

An isolated monospecific immunoglobulin composition from sera which recognizes a BabA antigen and binds said BabA antigen via a variable region and exhibits specific activity to a BabA adhesion protein from Helicobacter pylori, wherein said adhesin protein binds Lewisb and H-1 blood group antigen-glycoconjugates and is not a HopA, HopB, HopC, HopD or HopE protein.

### Claim 4 (depends on 3)

The immunoglobulin composition according to claim 3, wherein said BabA adhesin protein has a molecular weight in the interval of about 70 to 77 kDa as determined by SDS-PAGE.

### Claim 5 (depends on 3, 4)

The immunoglobulin composition according to any one of claims 3 or 4 wherein said BabA adhesin protein comprises the following amino acid sequence: EDDGFYTSVGYQIGEAAQMV (SEQ ID NO:5) or homologues thereof.

### Claim 6

An isolated monospecific antibody, which recognizes a BabA antigen and binds said BabA antigen via a variable region and exhibits specific activity to a BabA adhesion protein from Helicobacter pylori that binds Lewisb and H-1 blood group antigen-glycoconjugates and is not a HopA, HopB, HipC, HopD or HopE protein.

### Claim 7 (depends on 6)

The antibody according to claim 6, wherein said BabA adhesin protein has a molecular weight in the interval of about 70 to 77 kD as determined by SDS-PAGE.

### Claim 8 (depends on 6)

The antibody according to claim 6, wherein said BabA adhesin protein comprises the following amino acid sequence: EDDGFYTSVGYQIGEAAQMV (SEQ ID NO:5) or homologues thereof.

### Claim 9 (depends on 6)

The antibody according to claim 6, wherein said antibody is a monoclonal antibody.

### Claim 10 (depends on 3)

A method of manufacturing an immunoglobulin composition according to claim 3, comprising the following steps:
immunizing an animal with Lewisb binding protein or fractions thereof, expressed by Helicobacter pylori,
isolating the immunoglobulin fraction from an excretion of said host animal, and
purifying the immunoglobulin preparation to obtain an isolated monospecific immunoglobulin composition.

### Claim 11 (depends on 10)

The method according to claim 10, wherein said animal is a cow and the immunoglobulin fraction is isolated from the milk, preferably the colostrum thereof.

### Claim 12 (depends on 10)

The method according to claim 10, wherein said animal is a chicken and the immunoglobulin fraction is isolated from the egg yolk thereof.

### Claim 13 (depends on 6)

A method of manufacturing an antibody according to claim 6, wherein the method comprises the following steps:
immunizing an animal with a Lewisb binding protein (BabA) or fractions thereof, expressed by Helicobacter pylori, fusing immunised, immunoglobulin producing cells with a neoplastic cell line, selecting and growing cells expressing said antibody, and purifying the antibodies.

### Claim 14 (depends on 13)

The method of claim 13, further comprising expressing said antibody by a culture of viable microorganisms in an expression system, where said microorganism or organisms are generally recognized as safe (GRAS) and genetically modified to express said antibody.

### Claim 15 (depends on 14)

The method according to claim 14, wherein said microorganism is selected from the group consisting of bacteria of the species Lactobacillus, Staphylococcus and Enteriobacteriacea.

### Claim 16 (depends on 3)

A pharmaceutical preparation for treating an individual having or identified as being at risk of developing Helicobacter pylori infection, gastric ulcers or acid peptic disease in humans comprising the immunoglobulin composition according to claim 3.

### Claim 17 (depends on 3)

A method of treating an individual having or identified as being at risk of developing gastric ulcers comprising administering to a subject in need thereof the immunoglobulin composition according to claim 3.

### Claim 18 (depends on 3)

A method of treating an individual having or identified as being at risk of developing acid peptic disease comprising administering to a subject in need thereof the immunoglobulin composition according to claim 3.

### Claim 19 (depends on 6)

A pharmaceutical product for treating an individual having or being identified at risk of developing Helicobacter pylori infections, gastric ulcers or acid peptic disease in humans, comprising the antibody according to claim 6.

### Claim 20 (depends on 6)

A pharmaceutical product for treating an individual having or being identified at risk of developing gastric ulcers comprising the antibody according to claim 6.

### Claim 21 (depends on 6)

A pharmaceutical product for the treating an individual having or being identified at risk of developing peptic disease comprising the antibody according to claim 6.

### Claim 22 (depends on 18)

The method according to claim 18, wherein said subject is human and said immunoglobulin composition is administered orally.

### Claim 23 (depends on 6)

A method for treating a human having or being identified at risk of developing Helicobacter pylori infections, comprising orally administering an effective amount of an antibody according to claim 6 to said human.

### Claim 24 (depends on 8, 9)

A method of treating a human having or being identified at risk of developing Helicobacter pylori infections, said method comprising orally administering an effective amount of a culture of viable microorganisms in an expression system, wherein said microorganism or organisms are generally recognized as safe (GRAS) and genetically modified to express an antibody according to claim 8 or 9.

### Claim 25 (depends on 8, 9)

An expression system comprising a culture of viable microorganisms wherein said microorganism or organisms are generally recognized as safe (GRAS) and genetically modified to express an antibody according to claim 8 or 9.

### Claim 26 (depends on 1)

A method for treating a human having or being identified at risk of developing Helicobacter pylori infections, said method comprising orally administering an effective amount of a culture of viable microorganisms in an expression system, wherein said microorganisms or organisms are generally recognized as safe (GRAS) and genetically modified to express an adhesion protein according to claim 1.

### Claim 27 (depends on 4)

The composition according to claim 4, wherein the molecular weight of said BabA adhesin protein is in the interval of 73 to 75 kDa.

### Claim 28 (depends on 4)

The composition according to claim 4, wherein the molecular weight of said BabA adhesin protein is about 73.5 kDa.

### Claim 29 (depends on 6)

The antibody according to claim 6, wherein the molecular weight of said BabA adhesin protein is in the interval of 73 to 75 kDa.

### Claim 30 (depends on 4)

The antibody according to claim 4, wherein the molecular weight of said BabA adhesin protein is about 73.5 KDa.
